Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19: Study on paired series
Résumé
Abstract We designed a comparative study on two paired series of critical patients affected with Covid-19: the 1st group received Tocilizumab (TCZ) plus standard care (SC) versus a 2nd group which received only SC. Outcomes were: survival, mechanical ventilation (MV) and nosocomial infections. Ninety patients were included by pairing (n=45 in each group). 55.5% of SC group progressed to stage 3-acute respiratory distress syndrome (ARDS) versus 31% of TCZ+SC patients (p=0.03). No effect of TCZ was found on mortality (49% in each group, p=1) nor on MV use (p=0.67). ICU stay was more prolonged in TCZ+SC group (16 versus 8 days, p <10-3). The administration of TCZ induced a significant decrease in CRP but not changed the IL-6 dosage. Nosocomial infections occurred in 18 (40%) of TCZ+SC group comparatively to 15 (33,5%) of SC group, p=0.66. We concluded to no real clinical impact benefit of TCZ in this kind of patients.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 06/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →